Virtual Library

Start Your Search

F. Luo



Author of

  • +

    Poster Session (ID 8)

    • Event: ACLC 2018
    • Type: Poster Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
    • +

      P100 - Stem Cell Factor Leads to Lung Cancer Escapes from Anti-Angiogenic Therapy by Increasing the ALDH1+ Lung Cancer Cell Number (ID 146)

      00:00 - 00:00  |  Author(s): F. Luo

      • Abstract

      Background:
      Although the anti-angiogenic therapy becomes an important treatment for non-small-cell lung cancer, cancer cells can escape from this therapy through several different ways so as to keep growth. Our previous results showed that anti-angiogenic drugs increased the number of ALDH1+ lung cancer cells in mouse models. This study is to explore the significance and mechanism of this phenomenon.


      Method:
      The xenograft tumor murine models and molecular experiments in vitro were used in this study.


      Results:
      In our experiments with murine lung cancer xenografts, we found that the anti-angiogenic agent endostatin increased the number of ALDH1+ lung caner cells. In vitro results showed that SOX and OCT4 were highly expressed in ALDH1+ lung cancer cells. These cells had stronger ability in surviving in hypoxic environment, metastasis and invasion than ALDH1- lung cancer cells. We also found that the expressions of HIF-1a and stem cell factor (SCF) in the xenografts were increased after anti-angiogenic therapy. HIF-1? could up-regulate the expression of SCF in lung cancer cells. The over-expression of SCF can increase the proportion of ALDH1+ cells in lung cancer. The mechanism was related to the HIF-1?/SCF/c-Kit/PI3K/AKT pathway. Finally, when we combined anti-angiogenic therapy with decreasing SCF expression, it is found that the survival time of mice in the combination group was significantly longer than that in the single anti-angiogenic group.


      Conclusion:
      Anti-angiogenic therapy aggravated hypoxia which could induce the up-regulated expression of SCF in lung cancer. SCF promoted lung cancer to escape from anti-angiogenic therapy by increasing the number of ALDH1+ lung cancer cells.